Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Data Source
2.2. Study Population
2.3. Statistical Analysis
3. Results
4. Discussion
5. Limitations
6. Future Directions
7. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Taal, B.G.; Visser, O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004, 80 (Suppl. 1), 3–7. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D. Advances in neuroendocrine lung tumors. Ann. Oncol. 2010, 21 (Suppl. 7), vii65–vii71. [Google Scholar] [CrossRef] [PubMed]
- Rekhtman, N. Neuroendocrine tumors of the lung: An update. Arch. Pathol. Lab. Med. 2010, 134, 1628–1638. [Google Scholar] [CrossRef]
- Bertino, E.M.; Confer, P.D.; Colonna, J.E.; Ross, P.; Otterson, G.A. Pulmonary neuroendocrine/carcinoid tumors: A review article. Cancer 2009, 115, 4434–4441. [Google Scholar] [CrossRef] [PubMed]
- Gosain, R.; Mukherjee, S.; Yendamuri, S.S.; Iyer, R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers 2018, 10, 510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Travis, W.D.; Brambilla, E.; Nicholson, A.G.; Yatabe, Y.; Austin, J.H.M.; Beasley, M.B.; Chirieac, L.R.; Dacic, S.; Duhig, E.; Flieder, D.B.; et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac. Oncol. 2015, 10, 1243–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008, 26, 3063–3072. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017, 3, 1335–1342. [Google Scholar] [CrossRef]
- Gustafsson, B.I.; Kidd, M.; Chan, A.; Malfertheiner, M.V.; Modlin, I.M. Bronchopulmonary neuroendocrine tumors. Cancer 2008, 113, 5–21. [Google Scholar] [CrossRef]
- National Institutes of Health, National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Incidence Data, 1973–2015; National Institutes of Health, National Cancer Institute: Bethesda, MD, USA, 2021.
- Arrigoni, M.G.; Woolner, L.B.; Bernatz, P.E. Atypical carcinoid tumors of the lung. J. Thorac. Cardiovasc. Surg. 1972, 64, 413–421. [Google Scholar] [CrossRef]
- Iyoda, A.; Jiang, S.X.; Travis, W.D.; Kurouzu, N.; Ogawa, F.; Amano, H.; Sato, Y.; Rusch, V.W.; Saegusa, M.; Satoh, Y. Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Mol. Clin. Oncol. 2013, 1, 437–443. [Google Scholar] [CrossRef] [Green Version]
- Skuladottir, H.; Hirsch, F.R.; Hansen, H.H.; Olsen, J.H. Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002, 37, 127–135. [Google Scholar] [CrossRef]
- Petursdottir, A.; Sigurdardottir, J.; Fridriksson, B.M.; Johnsen, A.; Isaksson, H.J.; Hardardottir, H.; Jonsson, S.; Gudbjartsson, T. Pulmonary carcinoid tumours: Incidence, histology, and surgical outcome. A population-based study. Gen. Thorac. Cardiovasc. Surg. 2020, 68, 523–529. [Google Scholar] [CrossRef] [PubMed]
- Govindan, R.; Page, N.; Morgensztern, D.; Read, W.; Tierney, R.; Vlahiotis, A.; Spitznagel, E.L.; Piccirillo, J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006, 24, 4539–4544. [Google Scholar] [CrossRef] [PubMed]
- Fisseler-Eckhoff, A.; Demes, M. Neuroendocrine tumors of the lung. Cancers 2012, 4, 777–798. [Google Scholar] [CrossRef] [Green Version]
- Daskalakis, K.; Kaltsas, G.; Öberg, K.; Tsolakis, A.V. Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers. Neuroendocrinology 2018, 107, 355–365. [Google Scholar] [CrossRef] [PubMed]
- Gosain, R.; Ball, S.; Rana, N.; Groman, A.; Gage-Bouchard, E.; Dasari, A.; Mukherjee, S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 2020, 126, 792–799. [Google Scholar] [CrossRef]
- Aizer, A.A.; Chen, M.H.; McCarthy, E.P.; Mendu, M.L.; Koo, S.; Wilhite, T.J.; Graham, P.L.; Choueiri, T.K.; Hoffman, K.E.; Martin, N.E.; et al. Marital status and survival in patients with cancer. J. Clin. Oncol. 2013, 31, 3869–3876. [Google Scholar] [CrossRef]
- Gosain, R.; Groman, A.; Yendamuri, S.S.; Iyer, R.; Mukherjee, S. Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis. Anticancer Res. 2019, 39, 6835–6842. [Google Scholar] [CrossRef]
- Caplin, M.E.; Baudin, E.; Ferolla, P.; Filosso, P.; Garcia-Yuste, M.; Lim, E.; Oberg, K.; Pelosi, G.; Perren, A.; Rossi, R.E.; et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 2015, 26, 1604–1620. [Google Scholar] [CrossRef] [PubMed]
- Rekhtman, N.; Pietanza, M.C.; Hellmann, M.D.; Naidoo, J.; Arora, A.; Won, H.; Halpenny, D.F.; Wang, H.; Tian, S.K.; Litvak, A.M.; et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clin. Cancer Res. 2016, 22, 3618–3629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
SCLC | LCNEC | TC | AC | Other | p-Value | ||
---|---|---|---|---|---|---|---|
Count, N (%) | 103,890 (83) | 3303 (3) | 8146 (6) | 656 (1) | 8974 (7) | ||
Age, median (range in years) | 67 (15–99) | 66 (18–94) | 60 (10–96) | 62 (12–90) | 67 (12–99) | <0.01 | |
Race | NHW (%) | 86,251 (83) | 2595 (79) | 6648 (82) | 528 (80) | 7009 (78) | <0.01 |
NHB (%) | 8804 (9) | 397 (12) | 560 (7) | 46 (7) | 912 (10) | ||
Hispanic (%) | 4503 (4) | 168 (5) | 688 (8) | 57 (9) | 606 (7) | ||
Other (%) | 4332 (4) | 143 (4) | 250 (3) | 25 (4) | 447 (5) | ||
Sex | Male (%) | 53,661 (52) | 1849 (56) | 2690 (33) | 236 (36) | 4489 (50) | <0.01 |
Female (%) | 50,229 (48) | 1454 (44) | 5456 (67) | 420 (64) | 4485 (50) | ||
Staging | Localized | 5810 (6) | 659 (20) | 6021 (74) | 309 (47) | 1420 (16) | <0.01 |
Regional | 23,875 (23) | 869 (26) | 1390 (17) | 215 (33) | 1680 (19) | ||
Distant | 74,205 (71) | 1775 (54) | 735 (9) | 132 (20) | 5874 (65) | ||
Insurance | Not insured (%) | 1640 (2) | 72 (2) | 105 (1) | 11 (2) | 182 (2) | <0.01 |
Insured (%) | 40,742 (39) | 2260 (68) | 3879 (48) | 491 (75) | 4628 (52) | ||
Unknown (%) | 61,508 (59) | 971 (30) | 4162 (51) | 154 (23) | 4164 (46) |
Variable | OS Hazard Ratio | OS 95% Confidence Interval (CI) | DSS Hazard Ratio | DSS 95% Confidence Interval (CI) |
---|---|---|---|---|
Stage (II) vs. Stage (I) | 1.25 | 1.23–1.27 | 1.28 | 1.26–1.31 |
Stage (III/IV) vs. Stage (I) | 1.46 | 1.44–1.49 | 1.54 | 1.51–1.57 |
Regional vs. Localized | 1.56 | 1.54–1.57 | 1.89 | 1.86–1.91 |
Distant metastasis vs. Localized | 3.24 | 3.21–3.28 | 4.12 | 4.07–4.17 |
Female vs. Male | 0.81 | 0.80–0.81 | 0.83 | 0.82–0.83 |
TC vs. Adenocarcinoma | 0.30 | 0.28–0.31 | 0.16 | 0.15–0.17 |
AC vs. Adenocarcinoma | 0.55 | 0.48–0.62 | 0.52 | 0.45–0.60 |
SCLC vs. Adenocarcinoma | 1.11 | 1.10–1.12 | 1.11 | 1.10–1.12 |
LCNEC vs. Adenocarcinoma | 1.15 | 1.11–1.19 | 1.15 | 1.11–1.20 |
Race Hispanic vs. NHW NHB vs. NHW Other vs. NHW | 0.97 | 0.96–0.98 | 0.96 | 0.95–0.97 |
1.01 | 1.00–1.02 | 1.00* | 0.99–1.01 * | |
0.80 | 0.79–0.81 | 0.79 | 0.78–0.80 | |
Single vs. Married | 1.17 | 1.17–1.18 | 1.15 | 1.15–1.16 |
Uninsured vs. Insured | 1.22 | 1.19–1.25 | 1.19 | 1.16–1.23 |
Rural vs. Urban | 1.08 | 1.07–1.09 | 1.08 | 1.07–1.09 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shah, S.; Gosain, R.; Groman, A.; Gosain, R.; Dasari, A.; Halfdanarson, T.R.; Mukherjee, S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers 2021, 13, 1753. https://doi.org/10.3390/cancers13081753
Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers. 2021; 13(8):1753. https://doi.org/10.3390/cancers13081753
Chicago/Turabian StyleShah, Shrunjal, Rohit Gosain, Adrienne Groman, Rahul Gosain, Arvind Dasari, Thorvardur R. Halfdanarson, and Sarbajit Mukherjee. 2021. "Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States" Cancers 13, no. 8: 1753. https://doi.org/10.3390/cancers13081753
APA StyleShah, S., Gosain, R., Groman, A., Gosain, R., Dasari, A., Halfdanarson, T. R., & Mukherjee, S. (2021). Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers, 13(8), 1753. https://doi.org/10.3390/cancers13081753